Several studies involving different Hsp90 inhibitors have already demonstrated antifibrotic effects mediated by the inhibition of the TGF-β pathway in experimental models of lung fibrosis [51,52,53,54,55,56]. Here, TGFB1 is linked to pulmonary fibrosis.